Cai Jing Wang·2025-09-08 04:14Core Insights - The management of Junshi Biosciences discussed the commercialization progress of its products beyond Toripalimab during the 2025 semi-annual performance briefing [1] - The company is actively expanding sales channels for its commercialized products and is open to various types of business collaborations [2] Group 1: Product Commercialization - Mindewei® (Dexamethasone Hydrochloride Tablets) received conditional approval from the National Medical Products Administration in January 2023 and has achieved full-channel coverage by mid-2025, launching on major e-commerce platforms like Meituan, JD.com, and Ali Health [1] - Junmai Kang® (Adalimumab) has eight approved indications and is included in the national medical insurance catalog, with promotion responsibilities assigned to Maiwei Biopharmaceuticals [1] - Junshida® (Ongorilumab) was approved in October 2024 with three approved indications, and its commercialization efforts in mainland China are being advanced by partner Bochuang Pharmaceuticals [1] Group 2: Business Development Strategy - The business development team is actively working on aligning the company's pipeline with domestic and international resources, conducting in-depth research and communication on multiple potential collaboration directions [2] - The company maintains an open and proactive attitude towards various types of business cooperation and aims to accelerate pipeline research and development [2] - Regular reviews of the pipeline will be conducted to identify candidates with business development potential and share innovative results in a timely manner [2]